Skip to main content
. 2021 Jul 29;6:93. Originally published 2021 Apr 29. [Version 2] doi: 10.12688/wellcomeopenres.16594.2

Figure 12. HCV VL suppression first-line.

Figure 12.

( a) By duration randomisation. Note: EOT=end of treatment. Carrying forward last detectable value for participants meeting failure criteria. No evidence of difference between groups through day 28 when all participants were receiving DAAs (global p=0.13 comparing fixed-duration vs variable-duration combined; p=0.10 and 0.82 comparing VUS1 and VUS2 vs fixed, respectively). Post-EOT global p<0.0001 comparing fixed-duration vs variable-duration combined; p<0.0001 and 0.53 comparing VUS1 and VUS2 vs fixed, respectively. ( b) By ribavirin randomisation. Note: EOT=end of treatment. Carrying forward last detectable value for participants meeting failure criteria. No evidence of difference between groups through day 28 when all participants were receiving DAAs (global p=0.62 comparing ribavirin vs no ribavirin (combining fixed-duration vs variable-duration combined); interaction p=0.28). Post-EOT global p=0.48 comparing ribavirin vs no ribavirin (combining fixed-duration vs variable-duration combined; interaction p=0.22).